EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY
The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protei...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | STURGEON, CRAIG LAMMERS, KAREN MANON FASANO, ALESSIO GOLDBLUM, SIMEON SHEA-DONOHUE, TEREZ |
| description | The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR2). Also provided is a single step method for determining severity of an immune-mediated disease in a subject by identifying a genotype for haptoglobin 2 in a biological sample from the subject. A homozygous genotype correlates to 2 copies of zonulin and a more severe disease than a heterozygous genotype correlating to 1 copy of zonulin. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2791360A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2791360A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2791360A43</originalsourceid><addsrcrecordid>eNrjZDB2dXcLUnD0c1EIcAwyUghydQ_1cQzx9PdT8HdT8PQLcQ0O8fRz9FEIcA3ydXV08vTxDInkYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgFG5paGxmYGjibGRCgBAD6hJp0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY</title><source>esp@cenet</source><creator>STURGEON, CRAIG ; LAMMERS, KAREN MANON ; FASANO, ALESSIO ; GOLDBLUM, SIMEON ; SHEA-DONOHUE, TEREZ</creator><creatorcontrib>STURGEON, CRAIG ; LAMMERS, KAREN MANON ; FASANO, ALESSIO ; GOLDBLUM, SIMEON ; SHEA-DONOHUE, TEREZ</creatorcontrib><description>The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR2). Also provided is a single step method for determining severity of an immune-mediated disease in a subject by identifying a genotype for haptoglobin 2 in a biological sample from the subject. A homozygous genotype correlates to 2 copies of zonulin and a more severe disease than a heterozygous genotype correlating to 1 copy of zonulin.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160427&DB=EPODOC&CC=EP&NR=2791360A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160427&DB=EPODOC&CC=EP&NR=2791360A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>STURGEON, CRAIG</creatorcontrib><creatorcontrib>LAMMERS, KAREN MANON</creatorcontrib><creatorcontrib>FASANO, ALESSIO</creatorcontrib><creatorcontrib>GOLDBLUM, SIMEON</creatorcontrib><creatorcontrib>SHEA-DONOHUE, TEREZ</creatorcontrib><title>EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY</title><description>The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR2). Also provided is a single step method for determining severity of an immune-mediated disease in a subject by identifying a genotype for haptoglobin 2 in a biological sample from the subject. A homozygous genotype correlates to 2 copies of zonulin and a more severe disease than a heterozygous genotype correlating to 1 copy of zonulin.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB2dXcLUnD0c1EIcAwyUghydQ_1cQzx9PdT8HdT8PQLcQ0O8fRz9FEIcA3ydXV08vTxDInkYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgFG5paGxmYGjibGRCgBAD6hJp0</recordid><startdate>20160427</startdate><enddate>20160427</enddate><creator>STURGEON, CRAIG</creator><creator>LAMMERS, KAREN MANON</creator><creator>FASANO, ALESSIO</creator><creator>GOLDBLUM, SIMEON</creator><creator>SHEA-DONOHUE, TEREZ</creator><scope>EVB</scope></search><sort><creationdate>20160427</creationdate><title>EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY</title><author>STURGEON, CRAIG ; LAMMERS, KAREN MANON ; FASANO, ALESSIO ; GOLDBLUM, SIMEON ; SHEA-DONOHUE, TEREZ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2791360A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2016</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>STURGEON, CRAIG</creatorcontrib><creatorcontrib>LAMMERS, KAREN MANON</creatorcontrib><creatorcontrib>FASANO, ALESSIO</creatorcontrib><creatorcontrib>GOLDBLUM, SIMEON</creatorcontrib><creatorcontrib>SHEA-DONOHUE, TEREZ</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>STURGEON, CRAIG</au><au>LAMMERS, KAREN MANON</au><au>FASANO, ALESSIO</au><au>GOLDBLUM, SIMEON</au><au>SHEA-DONOHUE, TEREZ</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY</title><date>2016-04-27</date><risdate>2016</risdate><abstract>The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mRNA or protein. After diagnosis, the disease may be treated by decreasing cell permeability leading to increased transepithelial electrical resistance, for example, by administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting proteinase-activated receptor 2 (PAR2). Also provided is a single step method for determining severity of an immune-mediated disease in a subject by identifying a genotype for haptoglobin 2 in a biological sample from the subject. A homozygous genotype correlates to 2 copies of zonulin and a more severe disease than a heterozygous genotype correlating to 1 copy of zonulin.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP2791360A4 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A31%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=STURGEON,%20CRAIG&rft.date=2016-04-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2791360A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |